Adapting to Change

The US pharmaceutical landscape is in the midst of impactful shifts. A series of ambitious, aggressive, and often interconnected federal policy changes—from direct drug price controls and sweeping Pharmacy Benefit Manager reforms to strategic initiatives to reshore manufacturing and rapidly evolving FDA approaches—is creating a new reality for industry leaders, innovators, and strategists.
In this analysis, a federal policy expert unpacks the complex forces reshaping how life-saving therapies are researched, developed, manufactured, and delivered.